Literature DB >> 16891927

Fibroblastic rheumatism.

Riette du Toit1, J W Schneider, D A Whitelaw.   

Abstract

We report the first known South African case of fibroblastic rheumatism, a rare dermatoarthropathy. Our patient presented with the typical clinical features of a sudden-onset, erosive polyarthritis with cutaneous nodules and sclerodactyly. Significant functional loss occurred within a period of 3 to 4 months. X-rays of the hands showed a single erosion, whereas magnetic resonance imaging showed further erosions as well as soft tissue and synovial enhancement. The unique histologic findings of fibroblastic proliferation, thickened collagen, and dermal fibrosis confirmed the diagnosis of fibroblastic rheumatism. Our patient was treated with a combination of methotrexate and oral prednisolone with subsequent resolution of her synovitis/arthritis and no further progression of her sclerodactyly and associated functional loss. The course of fibroblastic rheumatism is known to vary and although multiple therapeutic options have been tried, the question remains whether any of the therapies alters the natural course of the disease. However, considering the probable role of lymphocytes and fibrogenic cytokines, an increased awareness with early diagnosis and treatment in the initial inflammatory stage may prevent the development of incapacitating joint sequelae.

Entities:  

Mesh:

Year:  2006        PMID: 16891927     DOI: 10.1097/01.rhu.0000231383.50323.b5

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  2 in total

1.  Good clinical response to methotrexate treatment in a patient with fibroblastic rheumatism.

Authors:  Juliane Aline Paupitz; Jozélio Freire de Carvalho
Journal:  Rheumatol Int       Date:  2010-03-26       Impact factor: 2.631

Review 2.  Fibroblastic rheumatism: an uncommon arthritis. A case-based review.

Authors:  A Pieta; A Zioga; A Skalkou; A I Venetsanopoulou; A A Drosos; P V Voulgari
Journal:  Rheumatol Int       Date:  2021-10-05       Impact factor: 2.631

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.